## Section 1332 of the Patient Protection and Affordable Care Act (PPACA) State Innovation Waivers – Reinsurance Waiver Quarterly Report

**Reporting Instructions:** Use the following template to capture data for quarterly 1332 waiver grant reporting, as specified in 45 CFR 155.1324(a), and referenced in your grant specific terms and conditions (STC). Quarterly reports are due 60 days following the end of each calendar quarter.

STATE: Maine				
		A. GRANTEE I	NFORMATION	
1. Reporting Period End Date			2. Report Due Date	
03/31/2025			5/30/2025	
Quarterly Quarterly		3rd Quarterly	4. Federal Agency and Organization Element to Which Report is Submitted	
Report	Report	Report	Consumer Information & Insurance Oversight (CCIIO)	
5. Federal Grant Number Assigned by Federal Agency		6a. DUNS Number		6b. EIN
1 SIWIW190005-01-00		160208815		016000001
7. Recipient Organ State of Maine -		l Access Reinsuranc	ee Association	
Address Line 1 254 Commercial	Street			
Address Line 2				
Address Line 3				
City State			Zip Code	
Portland	Portland ME			04101
Zip Extension		8. Grant Period Start Date		
			Jan 1, 2019	
9. Grant Period Er	nd Date			
12/31/27 (Grant	Period Extension a	approved 7/15/22)		
10. Other Attachn	nents (attach other	documents as neede	ed or as instructed b	y the awarding Federal agency)
None				

## Section 1332 of the Patient Protection and Affordable Care Act (PPACA) State Innovation Waivers - Reinsurance Waiver Quarterly Report

ERTIFICATION				
11. Certification: I certify to the best of my knowledge and belief that this report is correct and complete for performance of activities for the purposes set forth in the award documents.				
11b. Signature of Authorized Certifying Official				
(. M-				
11d. E-mail address				
choward@pierceatwood.com				
ON 1332 WAIVER - General				
ng and/or operating the approved 1332 waiver. n set to a corridor of \$135,000 to \$275,000 with a				

regards overall 2025 results. The 2024 final claims submissions are not due until July 20, 2025.

Section 1332 grant funding estimate of \$43,398,022 was received May 8, 2025 and is not reported in Q1 results.

13. Describe any implementation and/or operational challenges, including plans for and results of associated corrective actions. After the first quarter, only report on changes and/or updates, as appropriate.

No operational challenges have been experienced in 2025 YTD. See response to Question 12 above.

## Section 1332 of the Patient Protection and Affordable Care Act (PPACA) State Innovation Waivers — Reinsurance Waiver Quarterly Report

## Section 1332 of the Patient Protection and Affordable Care Act (PPACA) State Innovation Waivers — Reinsurance Waiver Quarterly Report

D. POST-AWARD FORUM
(for Quarter Post-Award Forum was held)
14. Was the date, time, and location of the Post-Award Forum advertised 30 days in advance?
CYes
No     No
15. State website address where Post-Award Forum was advertised
N/A
16. Date Post-Award Forum took place
The date for the 2025 Forum in process and notice will be published once the date isf inalized.
17. Summary of Post-Award Forum, held in accordance with §155.1320(c), including all public comments received and actions taken in response to concerns or comments.
The Summary of Post-Award Forum will be provided with MGARA's Q2 report.
18. Other Attachments (attach other documents as needed pertaining to Post-Award Form  None